BioStem Technologies, Inc.

What they do

BioStem processes placenta-derived human tissue into allografts used as protective barriers or coverings in advanced wound care and surgical settings. Its portfolio includes Neox and Clarix product lines, utilizing proprietary BioRetain, CryoTek, and SteriTek processing technologies. The company sells primarily to hospitals and physician offices through a direct sales force and independent agents, and it acquired the Neox and Clarix trademarks and related commercial infrastructure from BioTissue Holdings in January 2026.

Revenue drivers

• Neox and Clarix product sales — The primary revenue source after the January 2026 BioTissue asset acquisition, driving $7.9 million in Q2 2026 revenue.
• Hospital revenue — Generated $6.7 million in Q2 2026, up from $5.7 million in Q1 2026, representing the majority of net revenue.
• Physician office revenue — Contributed $1.1 million in Q2 2026, up from $0.8 million in Q1 2026.

Recent performance

For the second quarter of 2026, BioStem reported net revenue of $7.9 million, a 29% sequential increase from $6.1 million in Q1 2026 but down from $11.0 million in Q2 2025. Gross profit was $4.8 million with a 61% gross margin, flat sequentially but down from 94% in the prior-year quarter. GAAP net loss was $9.0 million, or $0.52 per share, compared to net income of $10,613 in Q2 2025. Adjusted EBITDA loss was $4.6 million, versus positive $2.5 million in Q2 2025. Cash and cash equivalents totaled $7.0 million as of June 30, 2026, down from $13.7 million at the end of Q1 2026.

Strategy

BioStem is integrating the Neox and Clarix assets acquired from BioTissue in January 2026 and scaling its commercial organization. It recently expanded its direct sales force, began integrating CRM and ERP systems, and transitioned major group purchasing organization agreements to broaden hospital access. The company uplisted to Nasdaq on August 7, 2026, and completed a $2.5 million private placement with its first institutional investor. It also issued eight new U.S. design patents for fenestrated human placental allograft technology.

Risks

• Revenue decline year-over-year — Q2 2026 revenue of $7.9 million was 28% below Q2 2025 revenue of $11.0 million, indicating a significant drop from prior-year levels.
• Gross margin compression — Gross margin fell to 61% in Q2 2026 from 94% in Q2 2025, materially reducing profitability on each dollar of sales.
• Cash burn and liquidity — Cash used in operations was $5.5 million in Q2 2026, leaving $7.0 million in cash, which may require additional financing.
• Contingent payment obligation — BioStem is required to pay BioTissue up to $10.0 million following the June 5, 2026 510(k) clearance of the Catalyze product, which could strain liquidity.

Outlook

Management raised full-year 2026 revenue guidance to $26 million to $29 million, up from a prior range of $25 million to $29 million. The company expects to continue scaling its commercial organization following the BioTissue acquisition and Nasdaq uplisting. However, it remains unprofitable on a GAAP basis and expects to continue investing in its commercial team and infrastructure.